Prior work presented by us identified, in both pre-clinical models and a phase 2 clinical trial of sapanisertib (NCT02417701), that lung squamous cell carcinomas (LUSC) harboring NRF2 activating mutations are sensitive to treatment with the TORC1/2 inhibitor sapanisertib. Further preclinical data suggests suppression glycolysis is potentiated targeting glutaminolysis helps fuel Krebs cycle, whi...